Psyence Group Inc. (PSYGF) Research

Psyence Group Inc. is a biotechnology firm operating in the life sciences sector, primarily focused on the commercial cultivation and production of psilocybin mushrooms. The company's naturally derived psilocybin is intended for therapeutic applications, targeting a variety of mental health conditions and other medical ailments. Currently, Psyence Group Inc. is engaged in formulating pharmaceutical-grade psilocybin dosages aimed at alleviating psychological trauma and specific diagnosable disorders, such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress associated with grief and bereavement. Furthermore, the company develops, distributes, and markets over-the-counter functional mushroom nutraceuticals, which are free of psilocybin, under its GOODMIND brand. Founded in 2019, Psyence Group Inc. is based in Toronto, Canada.

Market snapshot

Symbol
PSYGF
Price
$0.13
Day change
0.00%
Market cap
$1.9M
P/E ratio
-0.12x
52-week range
0.098-0.1394
Sector
Healthcare
Industry
Drug Manufacturers - General

Peer companies

  • Ayala Pharmaceuticals, Inc. (ADXS)
  • Aion Therapeutic Inc. (ANTCF)
  • Cryomass Technologies Inc. (CRYM)
  • Genix Pharmaceuticals Corporation (GENPF)
  • Indo Global Exchange(s) PTE, Ltd. (IGEX)
  • Kaya Holdings, Inc. (KAYS)
  • Resonate Blends, Inc. (KOAN)
  • Restart Life Sciences Corp. (NMLSF)

Open Psyence Group Inc. (PSYGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.